Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pholiota adiposa extract is a botanical extract derived from the edible mushroom *Pholiota adiposa*, commonly known as the chestnut mushroom. In preclinical studies, particularly for hepatocellular carcinoma (HCC), the ethanol extract (EPA) has demonstrated antitumor activity by inducing apoptosis and inhibiting angiogenesis. The mechanism involves the modulation of apoptosis-related proteins such as BAX, Bcl-2, and Cleaved Caspases, as well as the downregulation of Vascular Endothelial Growth Factor (VEGF). Additionally, the extract has been shown to modulate the intestinal microflora, increasing beneficial bacteria and decreasing harmful species, suggesting a potential role in the gut-liver axis for cancer therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pholiota adiposa extract.